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Abstract
Objective: Contact of blood with artificial surfaces and air as well as ischemia/reperfusion injury to the heart and lungs mediate systemic and
local inflammation during cardiopulmonary bypass (CPB). Activation of complement and coagulation cascades leads to and accompanies
endothelial cell damage. Therefore, endothelial-targeted cytoprotection with the complement inhibitor and endothelial protectant dextran
sulfate (DXS, MW 5000)may attenuate CBP-associatedmyocardial and pulmonary injury.Methods: Eighteen pigs (DXS, n = 10; phosphate buffered
saline [PBS], n = 8) underwent standard cardiopulmonary bypass. After aortic cross-clamping, cardiac arrest was initiatedwithmodified Buckberg
blood cardioplegia (BCP), repeated after 30 and 60 min with BCP containing either DXS (300 mg/10 ml, equivalent to 5 mg/kg) or 10 ml of PBS.
Following 30 min reperfusion, pigs were weaned from CPB. During 2 h of observation, cardiac function was monitored by echocardiography and
invasive pressure measurements. Inflammatory and coagulation markers were assessed regularly. Animals were then sacrificed and heart and
lungs analyzed. Results: DXS significantly reduced CK-MB levels (43.4  14.8 ng/ml PBS, 35.9  11.1 ng/ml DXS, p = 0.042) and significantly
diminished cytokine release: TNFalpha (1507.6  269.2 pg/ml PBS, 222.1  125.6 pg/ml DXS, p = 0.0071), IL1beta (1081.8  203.0 pg/ml PBS,
110.7  79.4 pg/ml DXS, p = 0.0071), IL-6 (173.0  91.5 pg/ml PBS, 40.8  19.4 pg/ml DXS, p = 0.002) and IL-8 (304.6  81.3 pg/ml PBS,
25.4  14.2 pg/ml DXS, p = 0.0071). Tissue endothelin-1 levels were significantly reduced (6.29  1.90 pg/100 mg PBS, 3.55  1.15 pg/
100 mg DXS p = 0.030) as well as thrombin—anti-thrombin formation (20.7  1.0 mg/ml PBS, 12.8  4.1 mg/ml DXS, p = 0.043). Also DXS reduced
cardiac and pulmonary complement deposition, neutrophil infiltration, hemorrhage and pulmonary edema (measured as lung water content,
81  3% vs 78  3%, p = 0.047), indicative of attenuated myocardial and pulmonary CPB-injury. Diastolic left ventricular function (measured as
dp/dtmin), pulmonary artery pressure (21  3 mmHg PBS, 19  3 mmHg DXS, p = 0.002) and right ventricular pressure (21  1 mmHg PBS,
19  3 mmHg DXS p = 0.021) were significantly improved with the use of DXS. Conclusions: Addition of DXS to the BCP solution ameliorates post-
CPB injury and to a certain extent improves cardiopulmonary function. Endothelial protection in addition to myocyte protection may improve
post-CPB outcome and recovery.
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In addition to surgical trauma, the use of cardiopulmonary
bypass (CPB) itself is associated with an acute pro-
inflammatory response [1] mainly caused by contact activa-
tion of blood with artificial surfaces and air, shear stress as
well as ischemia/reperfusion (IR) injury. Clinically, myocar-§ Yara Banz is a recipient of an MD-PhD grant of the Swiss Academy of Medical
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doi:10.1016/j.ejcts.2008.05.024dial damage ranging from stunning to necrosis with low
output syndrome and atrial fibrillation may occur, leading to
multiorgan failure in severe cases.
Activation of the coagulation and complement system,
leukocytes, endothelial cells and other pro-inflammatory
mediators, contribute to organ damage [2]. Complement
inhibition [3] and technical modifications such as ultrafiltra-
tion devices to remove excess water and pro-inflammatory
mediators [4], may improve clinical outcome to a certain
extent. However, the problem of CPB-associated inflamma-
tion and in particular IR-injury is not entirely prevented by
their use. Furthermore, cardiac arrest induced with cardi-
oplegic solution for the purpose of myocardial preservation
during CPB does not specifically protect the endothelium. IR-Surgery. Published by Elsevier B.V. All rights reserved.
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natural anticoagulant and anti-inflammatory surface glyco-
calyx layer [5] may, in part, contribute to CPB-associated
tissue damage. Restoration of an anti-inflammatory and anti-
coagulant environment through functional replacement of
the shed heparan sulfate proteoglycan (HSPG) may therefore
attenuate cardio-pulmonary dysfunction. To this purpose,
low molecular weight dextran sulfate (DXS, MW 5000), a
sulfated glycosaminoglycan analog and potent inhibitor of
complement [6,7] and coagulation [8] that has been shown to
bind to HSPG-denudated endothelium [7] and to ameliorate
acute myocardial IR-injury in vivo [9], was tested in a porcine
model of CPB. We hypothesized that DXS would preserve
cardiovascular and pulmonary function by complement
inhibition and endothelial cell protection in CPB mediated
inflammation and IR-injury.2. Materials and methods
Care and use of animals in the present study were in
compliance with the European Convention on Animal Care,
the respective Swiss national guidelines, and approved by the
Animal Care Committee of the Canton of Berne, Switzerland.
2.1. Animals and anesthesia
Eighteen large white pigs (60  3 kg) were premedicated
with intramuscular ketamine (20 mg/kg) and xylazine (2 mg/
kg), followed by intravenous administration of midazolam
(0.5 mg/kg) and atropine (0.05 mg/kg), and were intubated
and mechanically ventilated with a volume-controlled
ventilator (Servo 900, Siemens AG, Solna, Sweden) with
5 cm H2O end-expiratory pressure. Anesthesia was main-
tained with continuous intravenous infusion of pentobarbital
(8 mg/kg/h), fentanyl (0.03 mg/kg/h), and pancuronium
chloride (1 mg/kg/h) for muscle relaxation.
Arterial, central venous and Swan-Ganz catheters were
introduced into the internal and external jugular veins and
carotid artery respectively. The urinary bladder was
catheterized through a midline incision, and urinary output
measured regularly. Rectal and central venous blood
temperatures (thermistor in pulmonary artery catheter)
were measured continuously. A heating pad was used to
maintain the body temperature between 37.5—38.5 8C,
except during CPB-induced hypothermia.
2.2. Surgical procedure
A full midline sternotomy and pericardiotomy was
performed. Methylprednisolone (Solu-Medrol, Pfizer,
Canada, 1 g) was administered intravenously and the pigs
were heparinized with 400 IU/kg of heparin. Activated
clotting time (ACT) was controlled regularly using high-
range ACT cartridges (Medtronic, Minneapolis, MN) and an
automatized ACT analyzer (Medtronic HemoTec, Parker,
CO). If necessary additional heparin was administered to
keep ACTabove 250 s. A 5-F high-fidelity pressure-sensitive
tip transducer (Millar Instruments; Houston, TX) was
introduced through the base of the brachiocephalic trunk
into the left ventricle. Data were recorded with thePowerLab system (Chart 5.2, PowerLab, ADInstruments
Castle Hill, Australia).
2.3. Cardiopulmonary bypass (CPB)
A minimal extracorporeal circulation (MECC) system
comprising a membrane oxygenator (Quadrox, Jostra Inc.,
Hirrlingen, Germany) and a centrifugal pump (Jostra Inc.)
with a priming volume of 600—800 ml was used. Standard
aortic and bicaval cannulation was performed. A 7-F catheter
was inserted across the right atrium into the coronary sinus
for blood sampling throughout the experiment. Extracorpor-
eal circulation was performed with moderate systemic
hypothermia (32 8C) and a non-pulsatile mean flow rate of
3.3 (2.6—3.6) l/min/m2. Ringer solution or hydroxyethyl
starch was used for volume substitution. Antegrade cold
modified Buckberg blood cardioplegia (BCP, using Cardiople-
gin as the crystalloid cardioplegic solution) was administered
after aortic cross-clamping, initiating a period of 60 min of
cardiac arrest. Cold BCP (8 8C) was repeated after 30 min,
and warm BCP (35 8C) 30 min thereafter. To the two repeat-
cardioplegia solutions a total of either 10 ml phosphate
buffered saline (PBS, n = 8) or 10 ml of lowmolecular dextran
sulfate in PBS (DXS, MW 5000, Fluka Chemie, Buchs,
Switzerland, 300 mg, equivalent to a total of 5 mg/kg body
weight, n = 10) were added. The total volume of cardioplegia
solution used was weight-adapted and similar in both groups
(1420  520 ml and 1330  330 ml). After aortic declamping
a reperfusion phase of 30 min was initiated followed by
weaning off CPB and a post-CPB observation phase of
120 min. The animals were then sacrificed (intravenous
bolus of potassium chloride) and the heart and lungs excised
for further analysis.
2.4. Experimental groups
All experimenters were blinded with regard to treatment
regimen. Randomization of the animals into the two groups
was done prior to the experimental work, using a randomiza-
tion code (DXS = 0, PBS = 1), created by a random number
generator (SAS, version 9.1.2, SAS Institute Inc., Cary, NC,
USA). The samples (DXS solution or PBS) were prepared
according to the randomization output and stored at 20 8C
until use. Randomization and sample preparation was
performed by an independent laboratory technician. Prior
to premedication of the animals, the corresponding vial was
allocated to the pig (sequential number of vial = sequential
number of the pig). All 18 consecutively enlisted pigs were
treated according to this protocol. No animal was initially
excluded. Two experiments (DXS = 1, PBS = 1) were termi-
nated 1 h prematurely due to hemodynamic deterioration
after sudden, intractable arrhythmia and electromechanical
dissociation, respectively.
2.5. Hemodynamic monitoring and management
Heart rate, carotid and pulmonary arterial blood and
central venous pressures were recorded continuously. Right
ventricular and left atrial pressures were measured inva-
sively. Left ventricular pressure as well as dp/dtmax and dp/
dtmin were recorded with a 5-F high-fidelity pressure-
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continuously, all functional data were measured at following
time points: baseline, 30 min after cessation of CPB and
every 30 min thereafter. Mean arterial pressure was kept at a
minimum of 50 mmHg throughout the procedure, by adjust-
ing fluid balance (with hydroxyethyl starch) and noradrena-
lin, 5 mg boli, followed by continuous intravenous infusion if
pressure could not be maintained.
2.6. Echocardiography
Epicardial echocardiography was obtained using a transe-
sophageal (TEE) probe (ACUSON ultrasound system, Siemens,
Malvern, PA, USA) placed retrocardially to obtain following
views according to the standard TEE views: two and four
chamber views, transgastric midpapillary short axis view and
transgastric two chamber view. Left ventricular ejection
fraction was measured using the biplane method (or modified
Simpson method). Measurements were obtained at baseline
and simultaneously with other hemodynamic measurements.
2.7. Complement and coagulation
Blood samples were collected (EDTA plasma and serum) at
baseline, after going on CPB, after 30 and 60 min on CPB,
after 30 min weaning, and every 30 min thereafter. Samples
were kept on ice until centrifugation and stored at 80 8C
until further analysis.
Classical pathway complement activity (venous samples)
was determined by standard CH50 assay [10].
Activated partial thromboplastin time (aPTT, venous
samples) was measured using Dade Actin FS reagent in a
standard coagulation assay.
Thrombin—anti-thrombin III (TAT) complexes (coronary
sinus) were measured by micro-enzyme immunoassay
(Enzygnost Micro, Behringwerke AG, Marburg, Germany).
2.8. Ischemic and inflammatory markers
Circulating troponin I and creatine kinase (CK-MB fraction)
were determined by enzyme immunoassays (AxSYM micro-
particle enzyme immunoassay platform, Abbott laboratories,
Abbott Park, IL, USA) in coronary sinus blood samples. Both
assays were tested for cross-reactivity to porcine troponin I
and CK-MB. The effect of DXS in concentrations<1 mg/ml (in
the fluid phase) was tested and found to be negligible in the
multiplex suspension array setting described below in detail
(data not shown).
TNFalpha, IL-1beta, IL-6 and Il-8 were measured by
sandwich immunoassay using the Luminex fluorescent bead
technology. Matching antibody pairs (‘DuoSet’) specific for
porcine antigens were purchased from R&D Systems,
Minneapolis, MN, USA, and included anti-TNFalpha, anti-IL-
1beta, anti-IL-6 and anti-IL-8. The capture antibodies were
coupled to carboxylated beads using the Bio-Plex Amine
Coupling Kit (Bio-Rad Laboratories, Hercules, CA). The
biotinylated counterparts were used as the detection
antibodies. Analysis was done with the Bio-Plex system
(Bio-Rad Laboratories). Data analysis was done with Bio-Plex
Manager version 4.0 software (Bio-Rad Laboratories) with
five-parametric curve fitting.2.9. Endothelin-1 (ET-1)
Plasma and tissue ET-1 levels (coronary sinus samples)
were determined by specific radioimmunoassay after solid
phase extraction on C18 reverse phase columns as previously
described by Shaw et al. [11].
2.10. Histology and immunostaining
Representative samples from the heart and lungs were
fixed in 4% buffered formaldehyde, paraffin-embedded, and
3 mm sections stained with hematoxylin-eosin. Neutrophil
tissue numbers were determined by counting neutrophils in
10 randomly selected high power viewing fields from various
samples of each experiment. Five mm sections were cut from
all snap frozen tissue samples, air-dried, acetone fixed,
hydrated and labeled using a two/three-step indirect
immunofluorescence technique. The following antibodies
were used: rabbit anti-human C1q, C3b/c and C4b/c (Dako);
goat anti-human C6 (Quidel) cross-reactivity with the
respective porcine antigens was verified. Secondary anti-
bodies were goat anti-rabbit IgG(H + L)-FITC (Southern
Biotechnology Associated), rabbit anti-mouse Ig-FITC (Dako)
and biotinylated goat anti-rat IgG (Southern Biotechnology)
followed by streptavidin-FITC (Amersham Biosciences).
Samples from all experiments were stained and graded for
complement deposition: 0: no staining, 1: minimal focal or
diffuse staining, 2: moderately strong staining, 3: extensive
staining.
2.11. Tissue water content
Water content of the lungs was determined through
desiccation of the lungs at 100 8C for 48 h. Tissue water
content was calculated using the formula [(wet weight  dry
weight)/wet weight]  100.
2.12. Statistics
Non-parametric tests were used for data analyses because
of the relatively low number of data points rendering
assumption for Gaussian distribution of the data rather
speculative despite the fact that common tests did not reject
the hypothesis of normal distribution. Differences between
the two groups were compared by Mann—Whitney U-test. For
parameters measured over time, baseline values were
subtracted from the end-point measurements, to account
for random differences between the two groups at baseline.
All analyses were two-sided and differences were considered
statistically significant with a p value of <0.05. Analyses
involved baseline and end point measurements only, as
significant between-group differences (in biochemical mar-
kers) were expected at these time points. Repeated,
multiple testing was not performed to avoid corresponding
problems with type I errors.
According to Little’s test, missing values (max 15%) in the
datasets were all missing completely at random (MCAR). The
method of the last observation carried forward (LOCF) was
used for imputation of missing data.
SAS Version 9.1.2 (SAS Institute Inc., Cary, NC, USA) and
SPSS Version 12.0.1 (SPSS Inc., Chicago, IL, USA) software
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Fig. 1. Mean arterial pressure (MAP, A) and left ventricular (LV, B). Non-
significant trend towards improved MAP and LV pressure in the DXS-treated
animals during the post-CPB period. Monitoring of systolic (dp/dtmax, C) and
diastolic function (dp/dtmin, D), recorded by Millar catheter. Data are mean
 standard deviation.
Fig. 2. Right ventricular (RV) pressure (A) and pulmonary artery pressure (PAP,
B). Significant elevation at the end of the experiment in the PBS group as
compared to the DXS group (*p = 0.021 and *p = 0.002, respectively). Signifi-
cantly lower water content in the lungs (C, *p = 0.047) correlates with
decreased pulmonary damage (hemorrhage, neutrophil infiltration, edema)
in the DXS-treated animals (D). Data are mean  standard deviation. Scale bar
represents 100 mm.were used for all analyses. Data (corrected for hematocrit,
where appropriate) are presented as mean  standard
deviation.3. Results
3.1. Hemodynamics
Mean arterial pressure (MAP) at baseline was comparable
in both groups. At 30 min post-CPB, MAP was significantly
lower as compared to baseline in both groups. At the end of
the observation period, differences between both groups
were not significant (71  9 mmHg for DXS vs 54  10 mmHg
for PBS; p = 0.368, Fig. 1A). The total amount of noradre-
nalin (246  295 mg for DXS, 311  255 mg for PBS) or infused
hydroxyethyl starch (725  572 ml for DXS, 1035  893 ml
for PBS) needed to maintain the minimal target MAP of
50 mmHg until the end of the experiment did not differ
significantly between the two groups ( p = 0.261 and
p = 0.318, respectively). Following CPB and administration
of hydroxyethyl starch, hematocrit was significantly
reduced from average baseline values of 28.8  1.8% to
end point values of 21.6  2.2% ( p < 0.005). Baseline as well
as end point hematocrit values did not differ significantly
between the two groups ( p = 0.423 and p = 0.189, respec-
tively).
Mean left ventricular (LV) (Fig. 1B) as well as left atrial
(LA) pressure did not change significantly throughout the
post-CPB phase and were not significantly different from
baseline values in both groups (46  4 mmHg for DXS vs
43  5 mmHg for PBS; p = 0.669).
Systolic function, measured as dp/dtmax was slightly,
though not significantly, increased in both groups 30 min off
CPB and remained relatively stable throughout the remaining
post-CPB period (Fig. 1C, p = 0.989).
Diastolic function, measured as dp/dtmin, was impaired in
PBS controls during the post-CPB period as compared to
baseline ( p = 0.057 baseline vs end of experiment) and didnot fully recover until the end of the experiment, whereas
diastolic function remained relatively unchanged in the DXS
group (Fig. 1D, p = 0.782).
RV (Fig. 2A) and pulmonary artery pressures (Fig. 2B) post-
CPB were increased in both groups as compared to baseline,
and were significantly higher in the PBS controls as compared
to the DXS group at the end of the experiment ( p = 0.021 and
p = 0.002, respectively).
Episodes of atrial fibrillation occurred significantly less
frequently in the DXS as compared to the PBS group (total
episodes of arrhythmia: 9 times in the DXS group vs 18 times
in the PBS group, p = 0.006, not shown).
3.2. Echocardiography
LV ejection fraction remained stable and within normal
values during the whole procedure. No significant between-
group differences were noted at the end of the observation
period (68  11 mmHg for DXS vs 70  4 mmHg for PBS;
p = 0.341; p = 0.341, results not shown). LV regional wall
motion was preserved and similar in both groups.
3.3. Histology
Myocardial samples from both groups very focally
revealed changes consistent with IR damage including focal
wavy fibers and contraction bands, and were accompanied by
neutrophil infiltration (not shown). The severity of the
changes was more pronounced in samples from the PBS
group.
Samples of lung tissue revealed comparable non-specific
atelectatic changes in the lower lobes in both groups.
Neutrophil accumulation was observed in edematous septa as
well as in lung alveoli, particularly at sites of focal
hemorrhage. The extent of infiltration and edema was more
pronounced in PBS controls as compared to DXS treated
animals (Fig. 2C).
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Fig. 3. Thrombin anti-thrombin (TAT) in plasma samples. Rapid increase in TAT
production during CPB in the PBS group, with slow recovery post-CPB. Sig-
nificantly less TAT in the DXS group at the end of the observation period
(*p = 0.043). Data are mean  standard deviation.
Fig. 4. Troponin I (A) and creatine kinase (CK-MB, B) levels in coronary sinus
plasma samples. No significant differences at the end experiment between the
groups for troponin I levels. Significantly reduced levels of CK-MB in the DXS
group at the end of the observation period (*p = 0.042) Data are shown as
mean  standard deviation.
Fig. 5. TNFalpha, interleukin (IL-) 1beta, IL-6 and IL-8 levels in plasma
samples. Significantly elevated levels of all cytokines at the end of the
observation period as compared to PBS controls (TNFalpha: *p = 0.0071, IL-
1beta: *p = 0.0071, IL-6: *p = 0.002, IL-8: *p = 0.0071). Data are mean  stan-
standard deviation.3.4. Lung water content
Water content of the lungs was significantly higher in the
PBS controls as compared to the DXS treated animals (81  3%
vs 78  3%, p = 0.047) (Fig. 2C). This finding correlated with
increased histological signs of tissue edema in samples from
the PBS experiments (Fig. 2D).
3.5. Soluble coagulation and complement parameters
Baseline aPTT was comparable in both groups (DXS
32.8  4.4 s vs PBS 39.4  16.5 s; p = 0.317). Values
remained above 300 s in both groups following heparin
administration (not shown).
Thrombin anti-thrombin (TAT) levels markedly increased in
the PBS group during CPB and values were slow to recover,
whereas levels remained largely unchanged throughout in the
DXSgroup,with significantly less TATcomplexes than in the PBS
group at the end of the observation period (12.8  4.1 mg/ml
for DXS vs 20.7  1.0 mg/ml for PBS; p = 0.043, Fig. 3).
CH50 values (assessment of classical complement path-
way inhibition), decreased comparably in both groups and
were lower at the end of the experiment as compared to
baseline values. Values were comparable between both
groups (55  33% for DXS vs 68  24% for PBS; p = 0.648,
results not shown).
3.6. Markers of ischemia
Plasma troponin I values increased in both groups
throughout the experiment, but differences were not
statistically significant at the end of the observation period
(48.6  21.0 mg/ml for DXS vs 56.8  18.70 mg/ml for PBS;
p = 0.175, Fig. 4A). CK-MB values continuously increased in
both groups, with significantly increased values in the PBS as
compared to the DXS group at the end of the experiment
(peak levels 35.9  11.1 ng/ml for DXS vs 43.4  14.8 ng/ml
for PBS; p = 0.042, Fig. 4B).
3.7. Markers of inflammation
Plasma TNFalpha, IL-1beta, IL-6 as well as IL-8 levels
increased in both groups during the course of the experiment,and were significantly increased in the PBS controls as
compared to the DXS group at the end of the reperfusion
period (TNFalpha: 222.1  125.6 pg/ml for DXS vs 1507.6
 269.2 pg/ml for PBS, p = 0.0071; IL-1beta: 110.7 
79.4 pg/ml for DXS vs 1081.8  203.0 pg/ml for PBS,
p = 0.0071; IL-6: 40.8  19.4 pg/ml for DXS vs 173.0 
91.5 pg/ml for PBS; p = 0.002, IL-8: 25.4  14.2 pg/ml
for DXS vs 304.6  81.3 pg/ml for PBS, p = 0.0071;
Fig. 5A—D).
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Fig. 6. Significantly more endothelin-1 (ET-1) in myocardium in the PBS group
as compared to the DXS group (*p = 0.030). Data are mean  standard devia-
tion. Immunofluorescence staining for complement deposition (B). Grading
scores (mean  standard deviation) are indicated for each complement com-
ponent (*p = 0.004 for C4b/c and *p = 0.001 for C6). All images are represen-
tative of minimum four scored sections per experiment. Scale bar: 100 mm.3.8. Plasma and tissue endothelin-1
Plasma ET-1 levels increased moderately in both groups
during the experiment and were comparable between both
groups at the end of the observation period (8.33  1.27 pg/
ml for DXS vs 9.33  1.57 pg/ml for PBS; p = 0.406, not
shown). Significantly less ET-1 was detected in myocardial
tissue in the DXS group as compared to PBS controls
(3.55  1.15 pg/100 mg wet tissue for DXS vs 6.29 
1.90 pg/100 mg wet tissue in the PBS group p = 0.030,
Fig. 6A).
3.9. Immunostaining
In the DXS group myocardial complement deposition (C1q,
C4b/c, C3b/c, and C6) was reduced as compared with PBS
controls. Corresponding grading scores were: C1q: 0.5  0.5
for DXS vs 0.8  0.6 for PBS, p = 0.150; C4b/c: 1.5  0.5 for
DXS vs 2.4  0.7 for PBS, p = 0.004; C3b/c: 0.6  0.7 for DXS
vs 1.1  0.9, p = 0.120; C6: 0.8  0.5 for DXS vs 1.9  0.7 for
PBS, p = 0.001, Fig. 6B. Similarly also in lung tissue,
complement levels (C1q, C4b/c, C3b/c and C6) in the DXS
group were markedly reduced as compared to samples
obtained for the PBS control group (not shown).4. Discussion
The aim of this study was to assess measurable effects
of low molecular weight dextran sulfate (DXS) added to
standard blood cardioplegia in a setting similar to clinical
open-heart surgery. We have shown previously that DXS
functions as an (endothelial) cytoprotectant [7,8,13] and
attenuates myocardial reperfusion injury in vivo [9]. Our
hypothesis that DXS may preserve cardiovascular and
pulmonary function by complement inhibition and endothe-lial cytoprotection in CPB-mediated inflammation and IR-
injury has, at least in part, been confirmed by our findings.
With respect to cardiac function, DXS improved diastolic
function in comparison to PBS controls. Diastolic dysfunction
is frequently observed following open-heart surgery, may
have serious clinical implications and be difficult to treat.
Systolic function however, as measured by conductance
catheter and echocardiography, was unaffected. This may be
because systolic function remained essentially unaffected
throughout the experiment. Furthermore, echocardiography
may not be sensitive enough here to assess differences and
changes in ejection fraction of less than 5—10%. It therefore
remains speculative what, if any, effects DXS may have on
hearts with obviously impaired systolic LV function. Whilst
the reduction in inflammation (discussed below) may not
always correlate with improvement in clinical parameters
and outcome, a few such possible correlations are high-
lighted in the following paragraphs.
DXS significantly reduced episodes of atrial fibrillation in
this short-term post-CPB follow-up. From a clinical stand-
point, atrial fibrillation is still an important source of
postoperative morbidity and prolonged hospital stay, occur-
ring in up to 50% of patients after CPB [12]. The prospect of
reducing this rate is therefore desirable. Diminished local
cardiac inflammation following DXS use may partly be
responsible for the observed reduction of atrial fibrillation.
Indeed, the incidence of atrial fibrillation correlates with
inflammation [13]. Nevertheless, an important proportion of
hemodynamically relevant episodes of atrial fibrillation
manifest themselves 48—72 h postoperatively. In the short
post-CBP follow-up in the current study, no predictions can
be made as to the possibly continued, indirect positive anti-
arrhythmic effect DXS may have had in a later post-CBP
phase. DXS administration is associated with significant
attenuation of myocardial damage and complement deposi-
tion and evidently reduced CK-MB levels. Presently, although
a trend towards less troponin I in the DXS group was observed,
the differences did not reach statistical significance;
possibly because of a too short observation period, the peak
for troponin release being slightly delayed as compared to
CK-MB.
With respect to the lungs, DXS treated animals revealed
significantly less neutrophil infiltration, complement deposi-
tion and edema than controls, indicative of reduced
inflammation and possibly endothelial damage. As a positive
consequence thereof, pulmonary artery as well as right
ventricular (RV) pressures were significantly less elevated
after CPB in the DXS group compared to PBS controls.
Lung injury following CPB is multifactorial and includes
sequelae associated with IR-injury, changes in the integrity
of the bronchoalveolar architecture and infiltration by
inflammatory cells [14]. Such injury represents an important
cause of postoperative morbidity with high mortality, and
may lead to respiratory failure. Indirect attenuation of
pulmonary artery pressures, either by reducing the cuffing
effect on the arterioles provoked by accumulated lung
water, and/or preservation of diastolic LV function by DXS
may therefore prove critical in a clinical setting. Further-
more, preservation of perioperative RV function by DXS may
be central to ensure optimal postoperative recovery.
Indeed, the use of DXS (MW 8000) during CPB in a pediatric
Y. Banz et al. / European Journal of Cardio-thoracic Surgery 34 (2008) 653—660 659population has been shown to ameliorate immediate post-
CPB respiratory index [15].
A minimal extracorporeal circulation (MECC) system was
used in our experiments. This system has proven to be safe
and may also reduce morbidity as well as CPB-associated
inflammation in humans [16]. Whilst MECC may not yet be as
established as conventional ECC, precisely because of its
reduced pro-inflammatory potential it was utilized in this
study. Although differences in reduction of the anti-
inflammatory potential of a substance may be more difficult
to elucidate when the level of inflammation itself is possibly
lower than in a conventional ECC system, any differences
that are observed may be of even greater value. Indeed,
DXS modulated several components of inflammation and
coagulation.
Thrombin levels, measured as thrombin anti-thrombin
(TAT) complexes, rapidly increase after CPB [17]. Reduction
of thrombin generation by anti-thrombin III ameliorates IR-
injury by attenuating leukocyte recruitment [18]. Inhibition
of overall total thrombin production by DXS correlated
with reduced cardiac and pulmonary neutrophil recruitment
and may provide one mechanism by which damage was
ameliorated.
Systemic complement inhibition in CPB, including soluble
complement receptor type 1 [19] has proven beneficial in
ameliorating post-CPB recovery. C5b-9 directly contributes
to IR injury and lower levels are associated with reduced
complications and better recovery post-CPB [20]. Further-
more, C5b-9 levels correlate with lung water accumulation
and recovery of LV wall motion [19]. DXS reduced tissue
deposition of all complement components, including C5b-9 in
heart and lungs.
IL-6, an acute-phase inflammatory cytokine, is secreted
by activated endothelial cells, amongst others. Plasma IL-6 is
markedly increased following CPB and its production is
stimulated by thrombin [21]. Reduction of plasma IL-6,
possibly also in relation with a partial reduction in thrombin
production by DXS, may therefore play an important role in
curbing post-CPB inflammation. Furthermore, DXS also
significantly reduced TNFalpha, IL-1beta and IL-8 levels,
cytokines in part known to be activated and injurious during
CPB and cardiac surgery in general.
Not only high plasma ET-1, but also elevated tissue ET-1
levels have been shown to predispose to alterations in
pulmonary function and myocardial contractility [22].
Focally reduced tissue ET-1 levels after DXS treatment may
therefore have contributed to partly improved cardio-
pulmonary function post-CPB.
Of note, methylprednisolone (equivalent to 30 mg/kg)
was administered to all animals prior to the experiment to
prevent vasoplegia and hypotension as a reaction to CPB.
Whilst various clinical studies [23], have shown a positive
effect of methylprednisolone on reduction of inflammatory
responses, the effect on clinical outcome is not so clear and
certain patient populations may not necessarily benefit from
its use [24]. Whilst a certain overall reduction in inflamma-
tion may be attributable to the use of methylprednisolone in
this model, any methodological bias would be present in all
experiments, including the controls. Whether DXS, in the
applied dose, would suffice to reduce the inflammatory
response in an equivalent manner in a protocol lackingmethylprednisolone would have to be tested in further
experiments.
4.1. Study limitations
As with all experimental models, the animals used in this
CPB studywere healthy. Furthermore, with limited numbers in
each group, the power of this study is reduced. Additionally,
the observation period post-CPB may have been too short to
elucidate potentially significant, clinically relevant differ-
ences between the two groups. The use of hydroxyethyl starch
may influence inflammation. However, comparable amounts
were used in both groups, whereby observed differences
between the groups are unlikely to be due to its use. With the
aim tomimic a clinically realistic situation, we chose to adjust
the use of vasoactives and volume tomaintain amean pressure
of 50 mmHg, in effect however taking into account the limited
expressiveness of these pressure-based functional measure-
ments and the possibility of masking subtle influences of DXS
upon function. Indeed load independent determination of
cardiac function using a pressure-volume platformwould have
been able to provide more consistent and possibly more
reliable data. However, despite these limitations, we made
several reliable observations in a double-blinded pilot study
with settings closely mimicking clinical reality. Indeed, in the
complex setting of CBP-associated injury and inflammation,
even small advances in ameliorating aspects of post-CBP
damage may be of relevance for optimizing future treatment
strategies.
In summary, the addition of low molecular weight dextran
sulfate to standard blood cardioplegia significantly reduces
local complement activation in the heart and lungs as well as
the release of pro-inflammatory mediators. Furthermore,
DXS in part improved the hemodynamic situation by
ameliorating diastolic LV function and RV— and pulmonary
artery pressures post-CPB. Whilst DXS has been used in a few
patient trials [25], including CPB in children, [15] larger
randomized clinical trials would be needed before judging
the possible importance of the use of DXS in altering current
clinical practice. However, in light of the fact that DXS at the
current dose was not associated with any adverse events and
was well tolerated, it remains to be substantiated whether a
more aggressive treatment regimen, evaluated in a longer
post-CBP follow-up and ultimately analyzed in human trials,
may more markedly and sustainably improve post-CPB
cardiac function and outcome.Acknowledgements
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